Merus (NASDAQ:MRUS) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Merus (NASDAQ:MRUS) in a research report report published on Friday morning, Marketbeat.com reports. The firm issued an overweight rating and a $91.00 target price on the biotechnology company’s stock.

Several other equities analysts also recently weighed in on MRUS. UBS Group assumed coverage on Merus in a report on Thursday, October 24th. They set a “buy” rating and a $72.00 price target for the company. The Goldman Sachs Group began coverage on shares of Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $85.00 target price on shares of Merus in a research note on Monday, December 2nd. Needham & Company LLC reissued a “buy” rating and set a $85.00 price target on shares of Merus in a research report on Monday, December 9th. Finally, Guggenheim restated a “buy” rating and issued a $109.00 price objective (down from $111.00) on shares of Merus in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Merus presently has a consensus rating of “Buy” and an average price target of $86.08.

Merus Stock Performance

Merus stock opened at $41.25 on Friday. The stock’s 50 day moving average is $42.17 and its 200 day moving average is $47.82. Merus has a twelve month low of $37.66 and a twelve month high of $61.61.

Hedge Funds Weigh In On Merus

A number of institutional investors and hedge funds have recently modified their holdings of MRUS. Avior Wealth Management LLC bought a new position in Merus in the fourth quarter valued at about $76,000. nVerses Capital LLC increased its position in shares of Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 1,500 shares during the last quarter. US Bancorp DE bought a new position in shares of Merus in the 3rd quarter worth approximately $103,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Merus by 24.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after buying an additional 489 shares during the last quarter. Finally, MML Investors Services LLC bought a new stake in Merus during the third quarter valued at approximately $206,000. 96.14% of the stock is currently owned by hedge funds and other institutional investors.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.